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One can hardly think of any disease entity that has been the 
subject of as much controversy as hypertrophic cardiomy-
opathy. The core of the problem dates back to the initial 
pathophysiologic interpretations of the intraventricular gra-
dient with the conflicting concepts of outflow obstruction 
versus cavity obliteration (1-4). However, either as a con-
sequence of this early and basic dilemma or independently, 
controversy has also touched on the semantics, diagnosis, 
genetics and, obviously, management of hypertrophic car-
diomyopathy (5-16). 
Surgical and medical therapy of hypertrophic cardiomyop-
athy. The rationale for surgery in hypertrophic cardiomyop-
athy is based on the early concepts of functional sub aortic 
stenosis or dynamic obstruction impeding ejection out of the 
involved ventricle (1,2). A chunk of muscle is removed to 
increase the size of the outflow tract and decrease any 
significant impediment to flow (12). As the role of the 
anterior leaflet of the mitral valve in producing the obstruc-
tion became clearer (4,17), mitral valve replacement was 
proposed as the optimal approach to the mechanical correc-
tion of the problem (18). This idea was strongly challenged 
(19) and the indication for mitral valve replacement is 
currently restricted to a small group of patients in whom 
mitral regurgitation plays an important role (20). Thus, 
myotomy-myectomy remains the procedure of choice in the 
therapy of the obstructive type of hypertrophic cardiomyop-
athy (16). 
The increased emphasis on the functional and sometimes 
episodic nature of the obstruction, the growing recognition 
of the nonobstructive forms of hypertrophic cardiomyopathy 
and the gradual acceptance that intraventricular gradients 
may be generated by "cavity obliteration" contributed to 
increased interest in the medical therapy of this entity 
(8,13,14,21). The enthusiasm for medical therapy was further 
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enhanced by the realization that many of the symptoms of 
hypertrophic cardiomyopathy are related to abnormalities of 
diastolic function (22,23) and that arrhythmias were impor-
tant determinants of prognosis (24,25). Beta-adrenergic 
blockers, calcium channel antagonists and antiarrhythmic 
agents are now widely used with proved effectiveness (16). 
Propranolol, verapamil and disopyramide are, respectively, 
the most popular agents in each group. Medical management 
is usually the preferred choice in the vast majority of patients 
with hypertrophic cardiomyopathy, at least as initial ther-
apy. Surgery is reserved for the few severe and resistant 
cases that fail to respond or cannot tolerate the available 
pharmacologic agents. 
The present study. In this issue of the Journal, Seiler et 
al. (26) report the results of a retrospective study of 139 
patients diagnosed with hypertrophic cardiomyopathy over a 
period of approximately 30 years. Their focus is on the 
natural history of this entity, with attempts to compare the 
results of medical versus surgical therapy. In the process, 
the authors present a welcome review of numerous pub-
lished reports with regard to annual mortality and cumula-
tive survival rates in relation to the various therapeutic 
options. Their results are generally comparable with these 
published observations, which they have summarized in 
their Table 7, confirming that both medical therapy and 
surgical myotomy-myectomy tend to slightly decrease mor-
tality and modestly improve cumulative survival rates. 
The authors clearly state that the study is retrospective 
and that the groups of patients treated medically or surgi-
cally are not really comparable. They conclude, neverthe-
less. that "cumulative survival rate is significantly better in 
surgically than medically treated patients. " In addition, they 
report an operative mortality rate of 0% while the generally 
accepted operative risk is about 5% to 8% (16). Thus, either 
they have an unusually superior or lucky surgical team or 
they have selected lower risk patients. Therefore, their 
results may not be representative and there are grounds for 
concern about possible bias favoring surgical therapy. In 
fact, 42 of their patients were sent directly to surgery, a 
practice contrary to the current trend of sending to surgery 
only selective patients with severe disease who fail to 
respond or cannot tolerate medical therapy. 
Further, careful review of their data brings attention to 
the fact that in the medical group, patients receiving vera-
pamil did better than those receiving propranolol, and in the 
the surgical group, those who received verapamil after 
operation had a better outcome. Thus, another possible 
conclusion may be that verapamil rather than surgery may 
be the therapeutic approach that would best improve sur-
vival. However, both such a conclusion and the authors' 
conclusions regarding surgery are strongly limited by the 
fact that the groups selected may be even less comparable 
than the authors state. Only vague information regarding the 
diagnostic criteria used in the selection of patients is men-
tioned (27) and no information regarding the presence or 
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absence of arrhythmias or other factors that could affect 
prognosis in the various groups is provided (28). To attain 
more definitive conclusions. stricter definition of patients is 
necessary and all factors known to affect management and 
prognosis should be taken into consideration. 
The identity and types of hypertrophic cardiomyopathy. 
Hypertrophic cardiomyopathy has fascinated. intrigued and 
confused physicians and investigators for more than 3 dec-
ades. It took about 2 decades after its recognition before a 
relative consensus was reached regarding its current nomen-
clature (5.6.8.10). In the meantime. so many different names 
have been proposed that. despite the extensive number of 
published reports. the amount of true knowledge of this 
entity was questioned: "the less known about a disease 
state, the more names are given to it" (6). Questions about 
the identity of hypertrophic cardiomyopathy and controver-
sies surrounding it continued into the 1980s and persist until 
the present time (29.30). Difficulties in establishing satisfac-
tory diagnostic criteria have also persisted. Various pathog-
nomonic findings were proposed over the years. but did not 
withstand the test of time. Quantification of myocardial 
cellular disarray seems to be an accepted approach to 
establishing a pathologic diagnosis (16). However. the crite-
ria currently used for clinical diagnosis remain somewhat 
vague and variable (27). 
There is, nevertheless, (/ general telldellcy to thillk (~r 
suhtypes of hypertrophic cardiomyopathy: obstructive or 
nonobstructive; asymmetric or concentric; subaortic. mid-
ventricular or apical; and hypertrophic cardiomyopathy with 
or without cavity obliteration (21.27 J 1-34). Thorough 
angiographic or echocardiographic imaging. or both. is 
needed. in addition to the hemodynamic findings for appro-
priate characterization of subtypes. Overlap is frequent and 
hypertrophic cardiomyopathy may represent a spectrum of 
disease rather than a single well defined entity (9). Diffi-
culties encountered in defining and diagnosing hypertrophic 
cardiomyopathy will invariably affect any therapeutic trial. 
Although surgery may be clearly indicated in patients with 
true obstruction who do not respond to the available medical 
therapy. its role is questionable in patients who have an 
intraventricular gradient secondary to cavity obliteration. 
Thus. for definitive comparisons of therapeutic approaches 
to hypertrophic cardiomyopathy. prospective randomized 
trials in patients selected on the basis of strict and well 
defined diagnostic criteria are long overdue. 
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